Romosozumab increased spine and hip bone mineral density after 12 months of treatment.
Screening with bone measurement is recommended for women. Younger women are at more risk.
High levels of serotonin are predictive of an increased risk for hip fracture, nonvertebral osteoporotic fracture, and incident fractures in older men.
Romosozumab increased bone mineral density in postmenopausal women through increased bone formation and decreased bone resorption.
Men with accelerated bone loss have lower estimated bone strength, poorer trabecular microarchitecture, and thinner cortices compared with men without accelerated bone loss.
The USPSTF has released recommendations for vitamin D and calcium supplementation for the primary prevention of fractures in community-dwelling adults.
Researchers have determined that treatment for osteoporosis with teriparatide is associated with greater bone formation than treatment with zoledronic acid.
Researchers investigated the effects of growth hormone vs placebo, as well as the effects of sex steroid replacement therapy on bone mineral density in growth hormone-treated young adults with Prader-Willi syndrome who had attained adult height.
Researchers showed that decreased L1 trabecular attenuation is associated with increased risk for future osteoporotic fractures in adult patients aged ≥65 years undergoing abdominopelvic CT scans for other indications.
In postmenopausal women at high risk for fracture, treatment with romosozumab for 12 months, followed by alendronate, was associated with significantly fewer hip fractures than treatment with alendronate alone.
A recent literature review and meta-analysis indicates that growth hormone therapy may reduce the risk for fracture in patients with osteoporosis.
Teriparatide is associated with a lower risk for new vertebral and clinical fractures compared with risedronate in post-menopausal women being treated for severe osteoporosis.
In a randomized multidose trial, single doses of zoledronate (1-5 mg) prolonged antiresorptive activity ≥3 years in postmenopausal women with osteopenia.
Risk of vertebral fractures may be increased with discontinuation of denosumab therapy.
The task force recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women ≥65 years and postmenopausal women.
The FDA has requested data from 2 additional phase 3 clinical trials analyzing the safety and effectiveness of romosozumab, Amgen, Inc. and UCB's joint osteoporosis drug.
Daytime sleepiness and poor quality of sleep affect recurrent fall risk in the elderly.
An update to the 2008 ACP osteoporosis treatment guidelines focuses on treating low bone density and osteoporosis in an effort to prevent fractures.
Tuberculosis was identified as an independent risk factor associated with incident osteoporosis.
Eighty-four percent of survey respondents did not undergo osteoporosis pharmacotherapy following an osteoporosis-related fracture.
Tymlos approval was based on the results of the ACTIVE and ACTIVExtension trials.
The most common adverse events associated with long-term denosumab use were back, musculoskeletal, or extremity pain, hypercholesterolemia, and cystis.
The most important predictor for use of osteoporosis care was receiving primary care services within 6 months following hip fracture.
Researchers compared the efficacy of dual-energy x-ray absorptiometry with lateral x-ray in assessing vertebral fractures.
Fragility fracture risk increased with older age and decreased with higher bone mineral density in patients with type 1 diabetes.
Using dual-energy X-ray absorptiometry for bone age assessment complements traditional radiologic assessment.
Researchers evaluated trabecular bone scores in more than 100 women during either "legs up" or "legs down" dual energy x-ray absorptiometry scans.
Neither DXA-visceral adipose tissue nor android-gynoid fat mass ratios were associated with atherosclerotic cardiovascular disease events.
The Bone Health TeleECHO Clinic helps telementor healthcare professionals and improves osteoporosis care in underserved communities.
Testosterone treatment improved both bone mineral density and strength in older men.
Researchers found that female patients recovering from critical illness respond better to anti-fracture therapy for bone mineral density loss prevention compared with men.
Study examines the predictive value for vertebral fractures of bone mineral density and bone turnover markers after a 5-year drug holiday.
Two distinct time trends were observed in initiation of oral bisphosphonates in women after the 2008 updated osteoporosis treatment guidelines.
Patients with psoriatic arthritis or psoriasis had an increased prevalence of osteoporosis risk factors.
Bone Index announced that the Food and Drug Administration (FDA) has granted clearance for the second generation Bindex device model to aid in the diagnosis of osteoporosis.
A prospective cohort study in 66 patients with end-stage renal disease was conducted to determine the link between renal and coronary heart diseases.
For patients with type 2 diabetes, long-term use of dipeptidyl peptidase-4 (DPP-4) inhibitors is not associated with fracture risk.
Lorraine Fitzpatrick, MD, discusses updated results from the ACTIVE phase 3 clinical trial.
Researchers compared 3 classes of antihypertensive medication to determine hip and pelvic fracture risk in users vs nonusers.
Nancy E. Lane, MD, professor of medicine, at the University of California at Davis School of Medicine, discusses results from the phase 3 ACTIVE trial.
Heavy cannabis users have lower bone density compared to cigarette smokers.
Summer levels of serum 25-hydroxyvitamin D are associated with bone mineral density of the total hip.
The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) announced the publication of new clinical guidelines and an accompanying algorithm to help physicians and other health care professionals with the diagnosis, fracture risk assessment, and treatment of postmenopausal osteoporosis.
According to results from the TECOS trial, sitagliptin is not linked to an increased risk for fractures in patients with diabetes.
In postmenopausal women with osteoporosis, an experimental drug appears to reduce the risk of bone fractures better than teriparatide or a placebo.
An index accounting for both bone formation and resorption may help identify which women may experience faster bone loss during menopause.
For women initiating osteoporosis treatment, treatment-related changes in total hip bone mineral density (BMD) are associated with fracture risk.
Hormone Replacement Therapy vs Combination Oral Contraceptive for Bone Health in Premature Ovarian Failure
In women with premature ovarian failure, hormone replacement therapy was associated with greater increases in bone mineral density.
Proton pump inhibitor users had reduced mean femoral T-scores and increased frequency of osteoporosis and osteopenia.
Messages were linked to increased rates of DXA prescription and osteoporosis medication.
The strength of the correlation decreases with older parental age at hip fracture.
Researchers observed a 4% decrease in odds of bisphosphonate use each quarter after safety announcement for atrial fibrillation risk.
Case report describes osteonecrosis of the jaw in 80-year-old woman with diabetes.
Oral bisphosphonates appear to lower the risk for subsequent fracture and mortality after fracture.
Many older people unconcerned about or unaware of osteoporosis.
Asian women taking bisphosphonates may have a higher risk for atypical femur fracture than white women.
Treatment improved bone balance and reduced bone turnover.
The sclerostin inhibitor may increase bone strength at the spine and hip in postmenopausal women.
Variables included gender and age.
Denosumab treatment for up to 10 years is linked to persistent reduction in bone turnover and increased BMD.
Three or more cups per day may lower risk for fracture.
Fracture risk may be significantly lower in postmenopausal women with abaloparatide vs. teriparatide or placebo.
While these may serve as predictors, bone mineral density may not.
Researchers find no evidence that increasing intake will prevent fractures.
However, researcher says high cost, need to get shots in clinics make it an unlikely osteoporosis treatment.
An older women with type 2 diabetes and osteoporosis experienced improvements with one condition at the expense of the other.
A lower T-score for lumbar spine than femoral neck increases fracture risk, particularly in older women.
Prevalence of osteoporosis 16.2% in adults aged 65 years and older, while prevalence of low bone mass is 48.3%.
No increases were seen in bone density, muscle mass or mobility in postmenopausal women.
Resistance and jump training benefit middle-aged men.
The presence of urinary tract stones raises the risk for osteoporosis in men but not women.
Fracture risk is very low for younger postmenopausal women with no osteoporosis.
Researchers find patients at highest risk for fractures often miss out on tests, while those at low risk are being screened.
Cyclic treatment with teriparatide yields improvements in bone mineral density that are similar to daily treatment in women taking alendronate.
People with osteoporosis are nearly twice as likely to develop sudden deafness as those without the condition.
Higher muscle mass appears to be strongly associated with healthier bone development in young children.
A single IV dose of zoledronic acid improved bone mineral density in frail elderly women living in nursing homes and long-term care facilities.
Projections indicate that the incidence and costs of fractures related to osteoporosis will double by 2035 in China, according to new data.
Ever use of bisphosphonates associated with modest decrease in risk in cohort of nearly 90,000 postmenopausal women.
Women at high risk for fracture may have an increased risk for gum disease as well.
Residual life expectancy for 50- and 75-year-old man starting treatment estimated at 18.2 and 7.5 years.
In postmenopausal women, both weight gain and weight loss are associated with an increased incidence for fracture.
Postmenopausal women reported greater treatment satisfaction when switched from a once-monthly oral bisphosphonate to denosumab.
Despite recommendations, prescriptions for bisphosphonates remain low among men on androgen deprivation therapy.
Statin therapy with rosuvastatin did not reduce the risk for fracture among patients with high-sensitivity C-reactive protein levels.
Older men are less likely to be screened for osteoporosis or receive treatment after wrist fractures.
Men and women who drank more milk may have increased mortality risk, while women may also have an increased risk for fractures.
A BMI of 28 may serve as a better predictor of osteoporosis than other screening methods in younger postmenopausal women.
Resveratrol was linked to increases in spinal bone density in men with metabolic syndrome.
The FDA has approved a new indication with a new dose of Minivelle (estradiol transdermal system) for prevention of postmenopausal osteoporosis.
Women with higher vitamin D levels during midlife may have a lower risk for fractures.
Denosumab plus teriparatide increased bone density effected greater increases in bone density than either drug alone in women with osteoporosis.
Women with osteoporosis experienced increase in bone density and lower wrist fracture rates after treatment with denosumab.
Taking a break from bisphosphonates did not appear to be harmful in women with osteoporosis.
Zoledronic acid improved bone mass in frail, older women with osteoporosis for 3 years.
The Downton Fall Risk Index predicts fall-related hip fracture and other osteoporotic fractures in older men and women.
Good-quality evidence supports the efficacy of several medications for osteoporosis, but the comparative effectiveness of these drugs is unclear.
Bisphosphonate use, especially over a long duration, is associated with increased risk for atypical femoral fracture.
Raloxifene has a novel mechanism of action that may lead to a new class of drugs to treat osteoporosis.
More patients with abnormal bone mineral density should undergo screening for primary hyperparathyroidism.
Endocrinology Advisor Articles
- Diet Quality and Glycemic Control in Women With Gestational Diabetes
- Most Foods Containing Fructose Do Not Have Harmful Effect on Glycemic Control
- Effects of a Low-Carbohydrate Diet on Weight Loss Maintenance
- Sleep Quality in Women With Surgical vs Natural Menopause
- Unhealthy Lifestyle and Rotating Night Shifts Put Nurses at Higher Risk for T2D
- Hypothyroidism Treatment No Longer Available
- Obesity Subtype May Determine Outcomes After Bariatric Surgery
- Few Physicians Work in Practices That Use Telemedicine
- Skin Autofluorescence Predicts T2D, Heart Disease, Mortality
- ACC: Smoking Cessation Expert Decision Pathway Emphasizes Team-Based Support